Keywords: promise, wyeth, celltech, cma-676, wyeth-ayerst, investigational, compound
Promise With Wyeth And Celltech's CMA-676
Article | 26 May 1997
- Wyeth-Ayerst and Celltech's investigational compound CMA-676, whichcomprises an antibody linked to a new cytotoxic agent, has shown promise in a ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
